By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – A BG Medicine official said that the company has not pulled its initial public offering, despite being unable to price it thus far.

In an e-mail to GenomeWeb Daily News, Stacie Rader, senior vice president of executive operations and human resources for the firm, denied a Dow Jones Newswire article, which stated that the Waltham, Mass., biomarker development firm had abandoned its IPO because it had been unable to price it during the week.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The World Health Organization calls for the public release of clinical trial results within a year of the completion of data collection.

In Science this week: measles virus nucleocapsid structure, and more.

African and US health officials work to establish an Africa-wide Centres for Disease Control and Prevention.

Nature has retracted a 2002 epigenetics paper for image manipulation.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.